MedTrace Logo

The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors

NCT07651020 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2026-06-16

No results posted yet for this study

Summary

Here's a polished version of the text:

"This project involves patients with high-expression LRRC15 malignant tumors who are either clinically suspected of or diagnosed with pancreatic cancer, breast cancer, lung cancer, ovarian cancer, head and neck tumors, colorectal cancer, melanoma, etc., as well as healthy volunteers. Using a targeted LRRC15-specific SPECT imaging agent, SPECT/CT imaging is performed to achieve the following objectives:

For malignant tumor patients:

To support disease diagnosis and staging. Diagnostic performance will be evaluated against the gold standard of pathological diagnosis, clarifying the presence or absence of lesions and determining their location and nature.

To enable accurate staging and assess tumor burden by comparison with \[18F\]FDG PET/CT, thereby aiding in the determination of treatment plans.

For healthy volunteers:

To conduct pharmacokinetic analysis, elucidating the distribution, metabolism, and safety profile of the agent in the body."

Conditions

Interventions

DIAGNOSTIC_TEST

Specific SPECT imaging agents targeting LRRC15

This project utilizes LRRC15-specific targeted SPECT radiotracers to perform SPECT/CT imaging on healthy volunteers and patients with clinically suspected or confirmed malignancies characterized by high LRRC15 expression-including pancreatic cancer, breast cancer, lung cancer, sarcoma, head and neck tumors, glioblastoma, colorectal cancer, and melanoma.

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    lead OTHER

Principal Investigators

  • Xiaoli Lan, PhD · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2026-02-28
Completion
2026-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07651020 on ClinicalTrials.gov